Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Patenting RNA Interference Technology

Related Content

The Data Shift: UK Sets a New Course With 2025 Data (Use and Access) Act

Federal AI Moratorium Out, State AI Regulation Gold Rush In

One Big Beautiful Bill Act – Tax Highlights related to Research and Experimental Expenditures, Qualified Small Business Stock and Business Interest Expense Deductions

The Rise of Agentic AI: From Conversation to Action

Antitrust & Competition Technology Update Q1 2025

Trump 2.0 Tech Policy Rundown: 100 Days in, Federal Agencies Shift AI, Privacy, and Governance Priorities

Trump Administration Sets New Direction for AI Policy

Delaware Creates More Corporate Clarity and Overhauls Rules Governing Conflicted Transactions

Synopsys Completes Acquisition of Ansys

Goodwin Guides At One Ventures in First Investment in Stellaria Design

Goodwin Represents Levelpath on its Over $55 Million Series B Funding to Reimagine Enterprise Procurement, Led by Battery Ventures

Goodwin Is Number One Law Firm for Global M&A for H1 2025

Olo to be Taken Private by Thoma Bravo for Approximately $2.0 Billion

Goodwin Represents Superhuman in Agreement to Be Acquired by Grammarly

Goodwin Advised Landmark Bio in Acquisition by Artis BioSolutions to Expand Manufacturing and Commercialization of Advanced Therapies

Goodwin Advises Color Wow in its Pending Acquisition by L’Oréal

Technology

Life Sciences